Original Publication Date: 1 April, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Fabiana Ostronoff, Soheil Meshinchi & Elihu H Estey
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by accumulation of somatically acquired genetic alterations in hematopoietic progenitor cells. Cytogenetic analysis has been used for more than three decades and has allowed classifications of AML patients into distinct subsets that differ in biologic and prognostic characteristics [1,2].